CSL Behring

CSL Behring is one of the world's leading plasma protein biotherapeutics companies, specializing in the manufacture of therapies for the treatment of rare and serious diseases. Its line of therapies includes products for the treatment of hemophilia, von Willebrand Disease, and other bleeding disorders; immune deficiencies including primary immunodeficiency diseases (PIDD); hereditary angioedema and inherited respiratory disease. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in newborns.

Company Statistics

Parent Company: CSL Limited, (ASX:CSL), Melbourne, Australia</br>Headquarters: King of Prussia, PA</br>Employees: 9,000+Operations: In 19 countries</br>President: Paul PerreaultR&D: Marburg, Germany; Bern, Switzerland; King of Prussia, Pennsylvania, USA; Tokyo, Japan; Broadmeadows and Parkville, Victoria, Australia.

History

CSL Behring is a subsidiary of CSL Limited (ASX: CSL), a specialty biopharmaceutical company with headquarters in Parkville, Australia. As part of a global alignment, the CSL Behring brand was...
Read More